There seems to be a general pattern of a decline in dose-specific excess relative risk with increasing age at exposure [30].
Although there was a decline in ESA dose across the 60-month study period, the FDA black box warning issued in March 2007 did not appear to influence ESA prescribing for the overall dialysis population.
Most covariate strata also showed a decline in average dose between the two periods (P < 0.0001), except for Chain 3. Notably, Chain 3 (the largest nonprofit chain), which administers ~4.4% of all ESA doses, administered the lowest mean ESA dose both in the base and follow up periods compared to other medium and large dialysis facilities.
Using the electronic pharmacy database, we defined "intensification" as either 1) filling a prescription for a new oral diabetes medication or 2) filling a prescription for a higher dose of a previously prescribed medication, without a corresponding decline in dose of another oral diabetes medication within 1 month of the index visit (15).
This device uses β radiation from a strontium-90/yttrium-90 strontium-90/yttrium-90 strontium-90/yttrium-90in dosourceh increandng distasce from the source, it limits the radiation exposure to a defined region with little damage to adjacent tissues.
Although USRDS data show a decline in both ESA dose and hematocrit levels following the issuance of the FDA black box warning, it remained unclear, until now, whether these results were related to the FDA warnings or rather which groups, if any, benefited from the FDA warnings.
The treated groups had higher levels of both MMP-2 mRNA and protein activity than did the control group, although there was a decline in the high-dose group.
Doses of 3 μg/kg/d may prevent a decline in cord levels and doses up to 7 μg may be required to achieve concentrations above those in cords and close to concentrations found in healthy breast fed infants [ 95].
The dose of temozolomide explained a significant proportion of the observed heterogeneity, with higher doses generally associated with greater efficacy (MSR: χ=17.2, df=4; P<0.0043; volume: χ=91.7, df=3; P<0.0039), although there may have been a decline in efficacy at total doses above 1 g kg−1.
We found that doxorubicin causes a decline in microvascular density in a dose-dependent fashion.
